公开(公告)号：US20120244138A1

公开(公告)日：2012-09-27

申请号：US13428232

申请日：2012-03-23

Applicant: Andrew H-J. Wang ,  Shiuan-Woei Lin Wu ,  Fu-Chuo Peng ,  Che-An Wu

Inventor： Andrew H-J. Wang ,  Shiuan-Woei Lin Wu ,  Fu-Chuo Peng ,  Che-An Wu

IPC: A61K38/44 ,  C12P17/10 ,  C12N9/06 ,  A61P39/02

CPC classification number: C12P17/10 ,  A61K31/5513 ,  A61K38/443 ,  C12N9/0006 ,  C12Y101/01284 ,  Y02A50/473 ,  A61K2300/00

Abstract: Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants.

Abstract translation: 用硝基还原酶突变体解毒硝基苯并二氮杂的方法和组合物。

公开(公告)号：US08268969B2

公开(公告)日：2012-09-18

申请号：US12537129

申请日：2009-08-06

Applicant: Chi-Huey Wong ,  Chung-Yi Wu ,  Alice L. Yu ,  John Yu

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Alice L. Yu ,  John Yu

IPC: C07K16/00 ,  A01N43/04 ,  C07H17/00

CPC classification number: A61K39/0011 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C12N15/1137 ,  C12N2310/14

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CD1d on a dendritic cell, such as an α-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM197.

Abstract translation: 提供免疫原性组合物，癌症疫苗和治疗癌症的方法。 组合物，其包含：（a）聚糖如Globo H或其免疫原性片段，其中所述聚糖通过诸如对硝基苯基之类的接头与载体蛋白缀合; 和（b）包含能够结合树突状细胞上的CD1d的糖脂如α-半乳糖基 - 神经酰胺衍生物的佐剂，其中所述免疫原性组合物诱导与IgM同种型相比诱导更高相对水平的IgG同种型抗体的免疫应答 抗体。 提供了包含载体蛋白质白喉毒素交叉反应材料197（DT-CRM197）和佐剂C34的免疫原性组合物。 由本文公开的免疫原性组合物产生的抗体进一步中和至少一种抗原Globo H，阶段特异性胚胎抗原-3（SSEA-3）和阶段特异性胚胎抗原-4（SSEA-4）。 包括含有与DT-CRM197缀合的Globo H，SSEA-3或SSEA-4的免疫原性组合物的乳腺癌干细胞的治疗剂。

公开(公告)号：US20120231507A1

公开(公告)日：2012-09-13

申请号：US13046765

申请日：2011-03-13

Applicant: Yu-Chan CHAO ,  Chia-Jung Chang

Inventor： Yu-Chan CHAO ,  Chia-Jung Chang

IPC: C12P19/00 ,  C12N15/63 ,  C07H21/04 ,  C12N9/42

CPC classification number: C07H21/04 ,  C12N9/2437 ,  C12N15/63 ,  C12P19/00 ,  C12P19/02 ,  C12P19/14 ,  C12Y302/01004

Abstract: Two novel cellulases and nucleotide sequences encoding the same are disclosed. Also disclosed are compositions and methods for using the same for hydrolyzing cellulosic waste materials.

Abstract translation: 公开了两种新型纤维素酶及其编码的核苷酸序列。 还公开了用于水解纤维素废料的组合物和方法。

公开(公告)号：US08258464B2

公开(公告)日：2012-09-04

申请号：US12785945

申请日：2010-05-24

Applicant: Chung-Hsuan Chen ,  Chien-Hsun Chen ,  Jung-Lee Lin ,  Ming-Lee Chu

Inventor： Chung-Hsuan Chen ,  Chien-Hsun Chen ,  Jung-Lee Lin ,  Ming-Lee Chu

IPC: H01J49/34 ,  H01J37/244

CPC classification number: H01J49/025 ,  H01J49/0027

Abstract: A mass spectrometer and methods for obtaining the mass spectrum of a single macromolecular or biomolecular ion in a mass spectrometer. The methods include creating single macromolecular or biomolecular primary ions in an ion trap by ionization of a macromolecule or biomolecule; ejecting half of the primary ions for detection with a first charge detector; ejecting half of the primary ions to impact upon a conversion dynode, thereby creating secondary ions for detection with charge amplification detector such as a channeltron or an electromultiplier or an MCP.

Abstract translation: 质谱仪和在质谱仪中获得单个大分子或生物分子离子的质谱的方法。 该方法包括通过大分子或生物分子的离子化在离子阱中产生单个大分子或生物分子一级离子; 用第一电荷检测器喷射一半的初级离子用于检测; 喷射一半的初级离子以冲击转换倍增极，从而产生二次离子，以便用电荷放大检测器（例如通道电极或电倍增管或MCP）进行检测。

公开(公告)号：US20120213770A1

公开(公告)日：2012-08-23

申请号：US13106046

申请日：2011-05-12

Applicant: Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

Inventor： Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

IPC: A61K39/395 ,  A61P31/14 ,  A61P31/12

CPC classification number: C07K16/2851 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  G01N2333/18 ,  G01N2333/185 ,  G01N2500/02 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

Abstract translation: 鉴定当感染黄病毒如登革热病毒或日本脑炎病毒时诱导血浆渗漏和其它负面影响的细胞受体。 使用本文公开的融合蛋白，确定病原体（例如黄病毒）通过聚糖结合结合的受体。 一旦确定了受体，就可以确定与特定受体结合的作用，其中导致特定症状的受体的靶向可能被阻断病原体与受体结合的试剂所靶向。 因此，在登革热病毒和日本脑炎病毒的情况下，当病原体与DLVR1 / CLEC5A受体结合时，TNF-α被释放。 用单克隆抗体中断DLVR1 / CLEC5A受体降低TNF-α分泌，而不影响负责病毒清除的细胞因子分泌，从而将感染小鼠的存活率从零增加到约50％。

公开(公告)号：US20120207746A1

公开(公告)日：2012-08-16

申请号：US13203483

申请日：2010-02-25

Applicant: Tsewen Chang ,  Jiun-bo Chen ,  Pheidias C. Wu ,  Alfur F. Hung

Inventor： Tsewen Chang ,  Jiun-bo Chen ,  Pheidias C. Wu ,  Alfur F. Hung

IPC: A61K39/395 ,  C07K16/42 ,  A61P37/04 ,  A61P11/06 ,  A61P17/00 ,  A61K39/00 ,  A61P37/08

CPC classification number: C07K16/2803 ,  A61K39/39566 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP peptide at the C-terminal of CεmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, of CεmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

Abstract translation: 本发明涉及能够在人B淋巴细胞表面表达的膜结合IgE（mIgE）上有效结合C＆amp; mX结构域的抗体的产生和应用。 已经提出位于人膜结合的ε链上的CH4结构域和C末端膜锚定肽之间的52个氨基酸残基的Cys区域作为用于免疫靶向表达mIgE的B细胞的抗原位点。 以前报道的已报道的单克隆抗体，包括结合C C端的C端的RADWPGPP肽的α20已被发现与人B细胞上的mIgE结合不良。 我们已经发现，只有对特定片段特异性的单克隆抗体（如GLAGGSAQSQRAPDRVL和HSGQQGLPRAAGGSVPHPR）可以与人类B细胞有效结合，因此具有靶向这些B细胞用于治疗IgE介导的疾病的效用。

公开(公告)号：US20120129869A1

公开(公告)日：2012-05-24

申请号：US13294588

申请日：2011-11-11

Applicant: Yuh-Shan Jou ,  Yi-Wei Wang

Inventor： Yuh-Shan Jou ,  Yi-Wei Wang

IPC: A61K31/506 ,  G01N33/483 ,  A61P35/00 ,  A61K31/517 ,  A61K31/4545 ,  G01N33/574 ,  C12Q1/02

CPC classification number: G01N33/57423 ,  A61K31/4545 ,  A61K31/506 ,  G01N2333/91215

Abstract: The invention related to the use of high-density loss of heterozygosity (LOH) mapping in lung adenocarcinoma to identify intragenic LOH and driver mutations in different domains of ALK resulted in enhanced tumor growth in xenografted mouse. Mutant (H694R and E1384K) ALKs showed activation of Y1604 ALK and downstream AKT, STAT3 and ERK signaling pathways. Increases of oncogenic signalings resulted in enhanced cell proliferation, colony-formation, cell-migration and tumor-growth in xenografted mouse. Western blot and immunohistochemistry analysis using antibody against phospho-Y1604 ALK on 11 lung cancer cell-lines and 263 cancer specimens indicated ALK activation in all lung cancers regardless of tumor stages. Treating mutant-bearing mice with ALK inhibitor WHI-P 154 resulted in tumor shrinkage, metastasis suppression, and improved survival. Hyperphosphorylation of Y1604 ALK occurred early and continuously throughout tumor progression and could be used as a biomarker to detect lung cancer. Oncogenic ALK point mutations could be treatment targets for lung cancer.

Abstract translation: 本发明涉及在肺腺癌中使用高密度损失的杂合性（LOH）作图来识别ALK的不同结构域的内源性LOH和驱动突变导致异种移植小鼠中肿瘤生长增强。 突变体（H694R和E1384K）ALKs显示Y1604 ALK和下游AKT，STAT3和ERK信号通路的激活。 致癌信号的增加导致异种移植小鼠中增强的细胞增殖，集落形成，细胞迁移和肿瘤生长。 在11个肺癌细胞系和263个癌症标本上使用抗磷酸化Y1604 ALK的抗体进行蛋白质印迹和免疫组织化学分析，表明所有肺癌均不影响肿瘤阶段的ALK活化。 用ALK抑制剂WHI-P 154处理带突变体的小鼠导致肿瘤缩小，转移抑制和改善的存活。 Y1604 ALK的过度磷酸化在肿瘤进展期间早期和连续发生，可用作肺癌的生物标志物。 致癌性ALK点突变可能是肺癌的治疗靶点。

公开(公告)号：US20120129707A1

公开(公告)日：2012-05-24

申请号：US12949052

申请日：2010-11-18

Applicant: Yuh-Lin Wang ,  Ting-Yu Liu ,  Huai-Hsien Wang

Inventor： Yuh-Lin Wang ,  Ting-Yu Liu ,  Huai-Hsien Wang

IPC: C40B30/04 ,  C40B60/12

CPC classification number: G01N33/54353 ,  C40B30/06 ,  G01N21/658 ,  G01N33/553 ,  G01N33/56911 ,  G01N33/587

Abstract: A surface-enhanced Raman spectroscopic (SERS) system for detecting a biomolecule. The system includes a substrate, an array of nanoparticles disposed on the substrate, each being partially embedded in the substrate and having a non-embedded surface, and a linking agent disposed on the non-embedded surface of each of the nanoparticles. The array of nanoparticles has a uniform interparticle gap of 1-50 nm and the linking agent is capable of binding to the biomolecule.

Abstract translation: 用于检测生物分子的表面增强拉曼光谱（SERS）系统。 该系统包括衬底，布置在衬底上的纳米颗粒阵列，每个纳米颗粒部分地嵌入衬底中并具有非嵌入表面，以及设置在每个纳米颗粒的非嵌入表面上的连接剂。 纳米颗粒阵列具有1-50nm的均匀颗粒间隙，并且连接剂能够结合生物分子。

公开(公告)号：US20120108498A1

公开(公告)日：2012-05-03

申请号：US12896747

申请日：2010-10-01

Applicant: Tsung-Lin Li ,  Yu-Chen Liu ,  Yi-Shan Li ,  Syue-Yi Lyu

Inventor： Tsung-Lin Li ,  Yu-Chen Liu ,  Yi-Shan Li ,  Syue-Yi Lyu

IPC: A61K38/14 ,  A61P31/04 ,  A61K38/04 ,  C07K9/00 ,  C12P21/02

CPC classification number: C07K9/008 ,  A61K38/14

Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.

Abstract translation: 公开了包含式（I）化合物的新型药物组合物。 该新化合物可包括药学上可接受的载体。 本发明还包括使用Dbv29制备式（I）化合物的方法，以及式（I）化合物用于治疗细菌感染的方法。

公开(公告)号：US08158367B2

公开(公告)日：2012-04-17

申请号：US12485516

申请日：2009-06-16

Applicant: Chi-Huey Wong ,  Chung-Yi Wu ,  Cheng-Chi Wang ,  Alice L. Yu

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Cheng-Chi Wang ,  Alice L. Yu

IPC: G01N33/53

CPC classification number: G01N33/57488 ,  G01N33/57415

Abstract: A cancer diagnostic method using a glycan array that contains Gb5 and Globo H, Bb2, Bb3, and/or Bb4.

Abstract translation: 使用含有Gb5和Globo H，Bb2，Bb3和/或Bb4的聚糖阵列的癌症诊断方法。